Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Viscosupplementation Market

U.S. Viscosupplementation Market Trends

Report ID: GMI10692
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

U.S. Viscosupplementation Market Trends

The growing geriatric population prone to osteoarthritis is projected to fuel the market growth. The U.S. is experiencing a demographic shift characterized by a rapidly aging population.
For instance, according to the Population Reference Bureau, adults aged 65 and older are projected to increase from 58 million in 2022 to 82 million by 2050, and the share of the 65 and older age group of the total population is projected to grow from 17% in 2022 to 23% by 2050. This demographic trend translates to a larger pool of individuals at risk of developing osteoarthritis, a common age-related condition affecting the joints.
Additionally, conditions such as osteoarthritis are increasingly prevalent in the U.S. population, with clinical studies stating there are over 100 types of arthritis, and osteoarthritis is the most prevalent form of arthritis. Estimates suggest that the disease affects the aging population, with 43% of people suffering from osteoarthritis aged 65 and above.
These elderly individuals are more susceptible to developing osteoarthritis due to factors such as cumulative joint wear and tear, age-related changes in cartilage structure, and reduced joint resilience. Thus, as the geriatric population grows, the prevalence of osteoarthritis is expected to rise, driving demand for effective management strategies, including viscosupplementation.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. viscosupplementation market size was USD 1.1 billion in 2023 and is expected to register 7.6% CAGR from 2024-2032 owing to the rising prevalence of osteoarthritis, particularly in the aging population.

U.S. viscosupplementation industry from the 3 injections segment held 45.6% share in 2023 due to being supported by robust clinical evidence demonstrating its effectiveness in relieving symptoms of osteoarthritis and improving joint function.

U.S. viscosupplementation market from the non-avian segment is expected to reach USD 1.6 billion by 2032 due to reduced risk of allergic reactions, ethical and environmental considerations, and the assurance of consistency and purity with non-avian variety.

Bioventus Inc., Ferring Pharmaceutical, Fidia Farmaceutici S.p.A (Fidia Pharma USA Inc.), Lifecore Biomedical, Inc, Pacira BioSciences, Inc, Sanofi SA, Seikagaku Corporation, and Teva Pharmaceutical Industries Ltd., are some of the major viscosupplementation companies from the U.S.